MXPA05008704A - Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. - Google Patents
Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.Info
- Publication number
- MXPA05008704A MXPA05008704A MXPA05008704A MXPA05008704A MXPA05008704A MX PA05008704 A MXPA05008704 A MX PA05008704A MX PA05008704 A MXPA05008704 A MX PA05008704A MX PA05008704 A MXPA05008704 A MX PA05008704A MX PA05008704 A MXPA05008704 A MX PA05008704A
- Authority
- MX
- Mexico
- Prior art keywords
- interferon alpha
- improved
- improved properties
- fusion proteins
- alpha muteins
- Prior art date
Links
- 108010047761 Interferon-alpha Proteins 0.000 title abstract 3
- 102000006992 Interferon-alpha Human genes 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 108010078049 Interferon alpha-2 Proteins 0.000 abstract 1
- 102100039350 Interferon alpha-7 Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000004166 bioassay Methods 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invencion se refiere a interferon alfa humano y en particular a formas modificadas de interferon alfa 2 con propiedades mejoradas. Las proteinas mejoradas contienen sustituciones de aminoacidos en posiciones especificas que confieren actividad relativa incrementada en ensayos biologicos. La invencion proporciona tambien interferon alfa modificado con actividad biologica mejorada concomitante con un potencial inmunogenico reducido en la proteina. Las proteinas mejoradas estan disenadas para uso terapeutico en el tratamiento de enfermedades en humanos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03003647 | 2003-02-18 | ||
| PCT/EP2004/001524 WO2004074486A2 (en) | 2003-02-18 | 2004-02-18 | Fusion proteins of interferon alpha muteins with improved properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05008704A true MXPA05008704A (es) | 2005-10-05 |
Family
ID=32892853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05008704A MXPA05008704A (es) | 2003-02-18 | 2004-02-18 | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7456257B2 (es) |
| EP (1) | EP1594965A2 (es) |
| JP (1) | JP2007524351A (es) |
| KR (1) | KR20050107435A (es) |
| CN (1) | CN1751122A (es) |
| AU (1) | AU2004213565A1 (es) |
| BR (1) | BRPI0407533A (es) |
| CA (1) | CA2516293A1 (es) |
| MX (1) | MXPA05008704A (es) |
| PL (1) | PL376673A1 (es) |
| WO (1) | WO2004074486A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2498319A1 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| EA014157B1 (ru) * | 2005-06-29 | 2010-10-29 | Йеда Рисерч Энд Дивелопмент Ко. Лтд. | РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2) |
| CA2699944C (en) | 2007-09-21 | 2017-11-14 | The Regents Of The University Of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| US8623348B2 (en) * | 2009-03-27 | 2014-01-07 | Jw Pharmaceutical Corporation | Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP) |
| WO2011064758A2 (en) * | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| AU2012327877B2 (en) | 2011-10-28 | 2017-10-12 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| US8980267B2 (en) | 2012-03-03 | 2015-03-17 | Immungene Inc | Engineered antibody-interferon mutant fusion molecules |
| US9803021B2 (en) | 2012-12-07 | 2017-10-31 | The Regents Of The University Of California | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| PL3677591T3 (pl) | 2013-04-29 | 2023-06-26 | Teva Pharmaceuticals Australia Pty Ltd | Przeciwciała anty-cd38 i fuzje z interferonem alfa-2b o osłabionej aktywności |
| EP2994754B1 (en) * | 2013-05-10 | 2018-07-25 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Compositions and methods for simultaneous detection of hcv antigen/antibody |
| US10093745B2 (en) | 2013-05-29 | 2018-10-09 | The Regents Of The University Of California | Anti-CSPG4 fusions with interferon for the treatment of malignancy |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| UA125637C2 (uk) | 2014-10-29 | 2022-05-11 | Тева Фармасьютікалз Острейліа Пті Лтд | ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b |
| WO2017123548A1 (en) * | 2016-01-14 | 2017-07-20 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment |
| CN106065033A (zh) * | 2016-03-17 | 2016-11-02 | 中国药科大学 | 一种细胞因子融合抗体的制备及其应用 |
| WO2018014067A1 (en) | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd47 combination therapy |
| CA3076099A1 (en) * | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | Linkers for chimeric antigen receptors |
| CN111499718B (zh) * | 2019-01-30 | 2022-06-14 | 复旦大学 | 人α干扰素受体结合相关位点突变体及其用途 |
| JP2022529943A (ja) | 2019-04-15 | 2022-06-27 | クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー | がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
| CN116162171B (zh) | 2022-10-13 | 2025-06-03 | 深圳市百士通科技开发有限公司 | 抗体突变方法在治疗性抗体药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| WO1997033998A1 (en) * | 1996-03-14 | 1997-09-18 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
| HUP0201474A3 (en) * | 1999-05-19 | 2002-11-28 | Lexigen Pharmaceuticals Corp L | Expression and export of interferon-alpha proteins as fc fusion proteins |
| EP1379555A2 (en) * | 2001-03-02 | 2004-01-14 | MERCK PATENT GmbH | Modified interferon alpha with reduced immunogenicity |
| PL371675A1 (en) * | 2002-06-11 | 2005-06-27 | Merck Patent Gmbh | Method for mapping and eliminating t-cell epitopes |
| CA2498319A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| CA2500626A1 (en) * | 2002-10-01 | 2004-04-15 | Xencor, Inc. | Interferon variants with improved properties |
-
2004
- 2004-02-18 AU AU2004213565A patent/AU2004213565A1/en not_active Abandoned
- 2004-02-18 BR BRPI0407533-1A patent/BRPI0407533A/pt not_active Application Discontinuation
- 2004-02-18 JP JP2006501874A patent/JP2007524351A/ja active Pending
- 2004-02-18 EP EP04712037A patent/EP1594965A2/en not_active Withdrawn
- 2004-02-18 MX MXPA05008704A patent/MXPA05008704A/es not_active Application Discontinuation
- 2004-02-18 US US10/546,112 patent/US7456257B2/en not_active Expired - Fee Related
- 2004-02-18 KR KR1020057015254A patent/KR20050107435A/ko not_active Withdrawn
- 2004-02-18 PL PL376673A patent/PL376673A1/pl unknown
- 2004-02-18 WO PCT/EP2004/001524 patent/WO2004074486A2/en active Application Filing
- 2004-02-18 CA CA002516293A patent/CA2516293A1/en not_active Abandoned
- 2004-02-18 CN CNA2004800045242A patent/CN1751122A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050107435A (ko) | 2005-11-11 |
| EP1594965A2 (en) | 2005-11-16 |
| JP2007524351A (ja) | 2007-08-30 |
| WO2004074486A2 (en) | 2004-09-02 |
| WO2004074486A3 (en) | 2005-03-31 |
| BRPI0407533A (pt) | 2006-02-14 |
| US20070148739A1 (en) | 2007-06-28 |
| CA2516293A1 (en) | 2004-09-02 |
| AU2004213565A1 (en) | 2004-09-02 |
| CN1751122A (zh) | 2006-03-22 |
| PL376673A1 (pl) | 2006-01-09 |
| US7456257B2 (en) | 2008-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| DE602004011770D1 (de) | Fusionsproteine | |
| WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| PT698108E (pt) | Vectores adenovirais de origem animal e utilizacao em terapia genica | |
| WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
| EP1487493A4 (en) | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOACTIVE PEPTIDES | |
| WO2003103589A3 (en) | USE OF IL-21 IN THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS | |
| BR0315688A (pt) | Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas | |
| ATE389724T1 (de) | Menschliche dnase i hyperaktive varianten | |
| DK0914144T3 (da) | Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi | |
| DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
| NZ279963A (en) | Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946 | |
| GB0216972D0 (en) | Peptides and peptide derivaties for the treatment of &-synuclein-related diseases | |
| PL1636261T3 (pl) | Białka trombopoetynowe o ulepszonych właściwościach | |
| WO2004113386A3 (en) | Modified hirudin proteins and t-cell epitopes in hirudin | |
| WO2004050685A3 (en) | Antifungal therapeutic agents | |
| KR100488038B1 (ko) | 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도 | |
| WO2004034062A3 (en) | Use of cap-1 for the therapy of asthma | |
| BRPI0416507A (pt) | polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, uso de um polipeptìdeo, uma molécula de ácido nucleico, um vetor, ou uma célula hospedeira, composição farmacêutica, uso de um antagonista de citocina ou um agente anti-inflamatório, uso de polipeptìdeo,uma molécula de ácido nucleico, um vetor, ou uma célula hospedeira,e um antagonista de citocina ou um agente anti-inflamatório, método de tratamento de uma doença em um paciente, e para a identificação de um composto e, animal transgênico não humano | |
| EP2327723A3 (en) | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders | |
| IL313767A (en) | Use of the NEGR1 protein and its biologically active fragments in the medical treatment of ALK-related diseases | |
| DE59611330D1 (de) | Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen | |
| Critical Care Society of South Africa Working Group | Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated) | |
| DE112005002912A5 (de) | Pharmazeutisches Mittel umfassend Aminosäuren, Peptide, Proteine und/oder deren Bruchteile und Fragmente und deren Verwendung zur Prophylaxe und Behandlung von Defekten des Immunsystems bei Menschen und Tieren | |
| CY1113344T1 (el) | Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |